Oxford University to conduct Coronavirus Vaccine Human Testing Trials today

Coronavirus Vaccine Oxford University will start testing in humans with a COVID-19 Vaccine they developed from Thursday, the united kingdom government said in a press conference of Coronavirus. The first patients will receive a COVID-19 Vaccine developed Oxford from today, the UK government said which has made £20m (around $25m) in funding available for the project. Oxford University to conduct Coronavirus Vaccine Human Testing Trials today.

The Oxford team – led by Professor Sarah Gilbert, is testing ChAdOx1 COVID-19, a candidate supported a chimpanzee adenovirus modified to incorporate the spike or ‘S’ protein on the surface of SARS-CoV-2, the virus that causes COVID-19.

Oxford University corona vaccine human testing

The government-funded the vaccine project with 20 million pounds to Oxford and another 22 million pounds to a second vaccine project at Imperial College, London, Health Secretary Matt Hancock said on Wednesday, adding the project will help support phase 2 trials and help steel oneself against a bigger phase 3 study.

Hancock said a vaccine is that the 'best way' to defeat the virus and also bring the number of cases down within the country. He said the united kingdom government is committed to producing funding to make manufacturing capacity for vaccines if they prove effective in clinical testing.

Coronavirus Vaccine Human Testing 

The testing came because the death from coronavirus within the UK crossed the 18,000 marks. the world toll has already crossed 184,000. The vaccine is tested on around 500 volunteers and can specialize in safety and tolerability, in addition to providing an initial assessment of how effective the shot is.

WATCH: The NHS is open for non-#coronavirus services. People should call their GP if they are in need of advice or treatment. pic.twitter.com/t73SYJx7ol

— Matt Hancock (@MattHancock) April 22, 2020

The Imperial candidate has been developed by a team led by Professor Robin Shattock and is an mRNA vaccine against the S protein on SARS-CoV-2 – employing a similar approach to a vaccine developed by US biotech Moderna which is already in clinical trials.

Hancock said 'Both of those promising projects are making rapid progress and I have told the scientists leading them we are going to do everything in our power to support them,' 

Read Also: WHO Chief replied Trump over allegations